Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors

被引:29
|
作者
Aasen, Synnove Nymark [1 ,2 ]
Parajuli, Himalaya [1 ]
Tuyen Hoang [1 ]
Feng, Zichao [1 ,3 ]
Stokke, Krister [1 ]
Wang, Jiwei [1 ,3 ]
Roy, Kislay [1 ]
Bjerkvig, Rolf [1 ,4 ]
Knappskog, Stian [2 ,5 ]
Thorsen, Frits [1 ,4 ,6 ]
机构
[1] Univ Bergen, Kristian Gerhard Jebsen Brain Tumour Res Ctr, Dept Biomed, Jonas Lies Vei 91, N-5009 Bergen, Norway
[2] Haukeland Hosp, Dept Oncol & Med Phys, Jonas Lies Vei 65, N-5021 Bergen, Norway
[3] Shandong Univ, Brain Sci Res Inst, 44 Wenhuaxi Rd, Jinan 250100, Shandong, Peoples R China
[4] Luxembourg Inst Hlth, Dept Oncol, NorLux Neurooncol Lab, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg
[5] Univ Bergen, Sect Oncol, Dept Clin Sci, N-5020 Bergen, Norway
[6] Univ Bergen, Dept Biomed, Mol Imaging Ctr, Jonas Lies Vei 91, N-5009 Bergen, Norway
关键词
melanoma; brain metastasis; BRAF; MAPK; PI3K; combined treatment; apoptosis; CANCER CELLS; ACQUIRED-RESISTANCE; BUPARLISIB BKM120; BRAIN METASTASIS; DOSE-ESCALATION; IN-VITRO; MEK; APOPTOSIS; EXPRESSION; SURVIVIN;
D O I
10.3390/ijms20174235
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Malignant melanoma is the most aggressive type of skin cancer and is closely associated with the development of brain metastases. Despite aggressive treatment, the prognosis has traditionally been poor, necessitating improved therapies. In melanoma, the mitogen activated protein kinase and the phosphoinositide 3-kinase signaling pathways are commonly altered, and therapeutically inhibiting one of the pathways often upregulates the other, leading to resistance. Thus, combined treatment targeting both pathways is a promising strategy to overcome this. Here, we studied the in vitro and in vivo effects of the PI3K inhibitor buparlisib and the MEK1/2 inhibitor trametinib, used either as targeted monotherapies or in combination, on patient-derived melanoma brain metastasis cell lines. Scratch wound and trans-well assays were carried out to assess the migratory capacity of the cells upon drug treatment, whereas flow cytometry, apoptosis array and Western blots were used to study apoptosis. Finally, an in vivo treatment experiment was carried out on NOD/SCID mice. We show that combined therapy was more effective than monotherapy. Combined treatment also more effectively increased apoptosis, and inhibited tumor growth in vivo. This suggests a clinical potential of combined treatment to overcome ceased treatment activity which is often seen after monotherapies, and strongly encourages the evaluation of the treatment strategy on melanoma patients with brain metastases.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma
    Pedini, Francesca
    De Luca, Gabriele
    Felicetti, Federica
    Puglisi, Rossella
    Boe, Alessandra
    Arasi, Maria Beatrice
    Fratini, Federica
    Mattia, Gianfranco
    Spada, Massimo
    Caporali, Simona
    Biffoni, Mauro
    Giuliani, Alessandro
    Care, Alessandra
    Felli, Nadia
    MOLECULAR ONCOLOGY, 2019, 13 (09) : 1836 - 1854
  • [2] In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways
    Daphu, Inderjit
    Horn, Sindre
    Stieber, Daniel
    Varughese, Jobin K.
    Spriet, Endy
    Dale, Hege Avsnes
    Skaftnesmo, Kai Ove
    Bjerkvig, Rolf
    Thorsen, Frits
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (05) : 8773 - 8794
  • [3] PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma
    Corrales, Eyleen
    Levit-Zerdoun, Ella
    Metzger, Patrick
    Mertes, Ralf
    Lehmann, Ariane
    Munch, Julia
    Lemke, Steffen
    Kowar, Silke
    Boerries, Melanie
    CELL COMMUNICATION AND SIGNALING, 2022, 20 (01)
  • [4] PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma
    Eyleen Corrales
    Ella Levit-Zerdoun
    Patrick Metzger
    Ralf Mertes
    Ariane Lehmann
    Julia Münch
    Steffen Lemke
    Silke Kowar
    Melanie Boerries
    Cell Communication and Signaling, 20
  • [5] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [6] Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma
    Shull, Austin Y.
    Latham-Schwark, Alicia
    Ramasamy, Poornema
    Leskoske, Kristin
    Oroian, Dora
    Birtwistle, Marc R.
    Buckhaults, Phillip J.
    PLOS ONE, 2012, 7 (08):
  • [7] Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer
    Pappalardo, Francesco
    Russo, Giulia
    Candido, Saverio
    Pennisi, Marzio
    Cavalieri, Salvatore
    Motta, Santo
    McCubrey, James A.
    Nicoletti, Ferdinando
    Libra, Massimo
    PLOS ONE, 2016, 11 (03):
  • [8] COMBINED TREATMENT USING MAPK AND PI3K SIGNALING PATHWAYS INHIBITORS EFFECTIVELY REDUCES GROWTH OF MELANOMA BRAIN METASTASIS CELLS IN VITRO
    Saettem, M.
    Wang, J.
    Sundstrom, T.
    Thorsen, F.
    NEURO-ONCOLOGY, 2023, 25
  • [9] Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors
    Welker, Mark E.
    Kulik, George
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (14) : 4063 - 4091
  • [10] Influence of PI3K and MAPK Pathway Mutations on Response to Mono and Dual Treatment with Targeted Kinase Inhibitors
    McNeill, Robert S.
    Canoutas, Demitra A.
    Bash, Ryan E.
    Schmid, Ralf S.
    Constance, Brian H.
    Johnson, Gary L.
    Miller, C. Ryan
    FASEB JOURNAL, 2016, 30